A Phase 1, Multicenter, Open-label, Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion Following Autologous Stem Cell Transplant for Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Aldesleukin (Primary) ; PNK 007 (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 13 Feb 2017 Planned number of patients changed from 34 to 40.
- 13 Feb 2017 Planned End Date changed from 1 Aug 2019 to 1 Nov 2018.
- 13 Feb 2017 Planned primary completion date changed from 1 May 2019 to 1 Nov 2018.